From a GUARDANT360® database of NSCLC liquid biopsies, several ALK fusion partners could be identified: EML4 (85.4%), STRN (6%), as well as KCNQ, KLC1, KIF5B, PPM1B, and TGF. Additionally, liquid biopsies from 31 patients had been analyzed upon tumor progression under ALK inhibition. The gene discussed is ALK; the disease is neoplasm.